Delivery Order HHSN261201500036I-HHSN26100001
Award Date 9/22/15
Potential Completion Date 12/31/15
Potential Value $2.4K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Birmingham, AL 35294, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
8
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This task order was awarded under the PREVENT Preclinical Drug Development Program multiple award contract vehicle by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The task order, valued at approximately $2,400, is for a contract orientation and kickoff meeting to be provided by IIT Research Institute, the prime contractor, located in Chicago, Illinois. The period of performance is January 25, 2019 through February...
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma Health Sciences Center Division. The contract is part of the NCI's "PREVENT Cancer Program (PREVENT)" and covers a "CONTRACT ORIENTATION AND KICK-OFF MEETING" with a period of performance from September 22, 2015 to December 31, 2015. The contract has a ceiling value of $4,217.44 and is a Delivery Order...
- The National Cancer Institute awarded The Institute For Cancer Research a firm fixed-price delivery order valued at $1.24M under the PREVENT Preclinical Drug Development Program, with performance scheduled to conclude on November 17, 2026. This task order, titled "Next Generation GP130/IL-6/STAT3 Inhibitors for the Prevention of Colitis-Associated Colorectal Cancer," was awarded on May 18, 2022, without set-aside designation. The Institute For Cancer Research, a non-profit subsidiary...
- This federal contract award is a $2,000 delivery order issued against the PREVENT Preclinical Drug Development Program master IDIQ by the National Cancer Institute. The University of Oklahoma Health Sciences Center, as prime contractor, will provide contract orientation and kickoff meeting services from January to February 2019 in Oklahoma City. The purpose of the PREVENT program, managed by the National Institutes of Health, is to support preclinical efficacy testing of novel cancer...
- The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through January...
- This is a federal contract award to The Medical College of Wisconsin, Inc. (MCW) to provide services under the "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" program. The contract, issued by the National Cancer Institute (NCI), is a Delivery Order with a ceiling value of $3,599.64 and a period of performance from September 22, 2015 to December 31, 2015. The contract is part of the larger "PREVENT Cancer Program (PREVENT)"...
- The National Cancer Institute awarded a $1.57 million firm fixed-price delivery order to The Institute for Cancer Research (ICR) on September 15, 2022, for preclinical drug development services supporting the PREVENT (Preclinical Drug Development Program) initiative. The task order, titled "Microbial Metabolite Mimicry, A Nano-Drug for Colon Cancer Prevention," focuses on preclinical efficacy evaluation and intermediate endpoint biomarker identification for candidate chemopreventive...
- The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, was awarded a $779,932 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) multiple award master indefinite delivery contract held by the National Cancer Institute. The delivery order, with a completion date of March 2025, will fund continued evaluation of candidate chemopreventive and immunopreventive regimens to support the goals of the PREVENT program in...
- This federal contract award with award ID HHSN261201500024I|HHSN26100003 was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS). The $321,110.80 award was made on September 15, 2016 to the IIT Research Institute (IITRI), a non-profit research organization and division of the Illinois Institute of Technology (IIT). The contract is for the "PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS" under the NCI's PREVENT...
- The National Cancer Institute awarded a $1.98 million firm fixed-price delivery order to IIT Research Institute (IITRI) on September 17, 2018, for preclinical studies supporting clinical trial development of an MPGES-1/5-LOX inhibitor therapeutic candidate. The contract, which was ultimately completed by July 25, 2025, was performed at IITRI's Chicago, Illinois facility and encompassed toxicology and pharmacology testing services required to support investigational new drug applications and...